These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25380840)

  • 21. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
    Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
    BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
    Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation.
    Liu Y; Liu R; Fu P; Du F; Hong Y; Yao M; Zhang X; Zheng S
    Cell Physiol Biochem; 2015; 36(6):2494-503. PubMed ID: 26279450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
    Farhan M; Malik A; Ullah MF; Afaq S; Faisal M; Farooqi AA; Biersack B; Schobert R; Ahmad A
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing of periostin inhibits nicotine-mediated tumor cell growth and epithelial-mesenchymal transition in lung cancer cells.
    Wu SQ; Lv YE; Lin BH; Luo LM; Lv SL; Bi AH; Jia YS
    Mol Med Rep; 2013 Mar; 7(3):875-80. PubMed ID: 23314871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chrysotobibenzyl inhibition of lung cancer cell migration through Caveolin-1-dependent mediation of the integrin switch and the sensitization of lung cancer cells to cisplatin-mediated apoptosis.
    Petpiroon N; Bhummaphan N; Tungsukruthai S; Pinkhien T; Maiuthed A; Sritularak B; Chanvorachote P
    Phytomedicine; 2019 May; 58():152888. PubMed ID: 30901662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
    Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
    Wong JC; Bathina M; Fiscus RR
    J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.
    Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
    Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
    Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
    Lung Cancer; 2009 Feb; 63(2):219-26. PubMed ID: 18599154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
    Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
    Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer.
    Xu K; Liu B; Liu Y
    Mol Med Rep; 2015 Jul; 12(1):995-1001. PubMed ID: 25683840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
    Gao W; Liu Y; Qin R; Liu D; Feng Q
    Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells.
    Duan L; Shen H; Zhao G; Yang R; Cai X; Zhang L; Jin C; Huang Y
    Biochem Biophys Res Commun; 2014 Apr; 446(4):1010-6. PubMed ID: 24657266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deguelin inhibits epithelial-to-mesenchymal transition and metastasis of human non-small cell lung cancer cells by regulating NIMA-related kinase 2.
    Zhao D; Han W; Liu X; Cui D; Chen Y
    Thorac Cancer; 2017 Jul; 8(4):320-327. PubMed ID: 28509438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.